Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.
Even during a down period for the markets, Pfizer has gone against the grain, climbing to $28.30. Its shares have yielded a 7 ...
Poland and Romania have been ordered by a Belgian court to pay Pfizer Inc. €1.9 billion ($2.2 billion) for Covid-19 vaccines ...
Pharmaceutical companies AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth-quarter ...
Pfizer is playing catch-up in the GLP-1 weight-loss space. The drugmaker is getting closer and closer to key patent cliffs. Investors should also note that Pfizer's payout ratio is worryingly high.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results